HaptoGuard

HaptoGuard is a Swiss biotechnology company focused on developing haptoglobin-based therapies to treat hemolytic diseases, such as sickle cell disease and beta-thalassemia. As a spin-off from the University of Zurich, the company utilizes its deep understanding of the haptoglobin-hemoglobin-CD163 pathway to neutralize the toxic effects of cell-free hemoglobin. Their lead program involves a recombinant human haptoglobin designed to prevent vascular complications and organ damage associated with chronic hemolysis. HaptoGuard's approach aims to address the underlying pathophysiology of these conditions by restoring the body's natural scavenging capacity for toxic heme-containing proteins. The company is currently advancing its lead candidate through pre-clinical development with the goal of entering clinical trials.